UroGen Announces First Patient Dosed in Phase 1 Trial of UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma announced the first patient dosing in a Phase 1 clinical trial of UGN-501, an investigational next-generation oncolytic virus designed to treat non-muscle invasive bladder cancer (NMIBC). The open-label, dose-escalation trial will evaluate safety, tolerability, and pharmacokinetics of intravesical administration in patients with recurrent NMIBC. The company is also conducting parallel nonclinical studies exploring UGN-501 formulation with its proprietary RTGel technology.